Equities research analysts expect Audentes Therapeutics Inc (NASDAQ:BOLD) to report earnings per share (EPS) of ($0.91) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Audentes Therapeutics’ earnings, with estimates ranging from ($1.02) to ($0.84). Audentes Therapeutics reported earnings per share of ($0.82) during the same quarter last year, which indicates a negative year over year growth rate of 11%. The company is expected to issue its next earnings report on Thursday, March 14th.
On average, analysts expect that Audentes Therapeutics will report full year earnings of ($3.38) per share for the current fiscal year, with EPS estimates ranging from ($3.60) to ($2.99). For the next financial year, analysts forecast that the firm will report earnings of ($3.86) per share, with EPS estimates ranging from ($4.53) to ($3.18). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for Audentes Therapeutics.
Audentes Therapeutics (NASDAQ:BOLD) last announced its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.97) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.88) by ($0.09). During the same quarter in the previous year, the company posted ($0.88) earnings per share.
In other news, Director Louis G. Lange sold 33,000 shares of the business’s stock in a transaction dated Monday, September 24th. The stock was sold at an average price of $37.38, for a total transaction of $1,233,540.00. Following the completion of the transaction, the director now owns 365,999 shares of the company’s stock, valued at $13,681,042.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Matthew R. Patterson sold 12,952 shares of the business’s stock in a transaction dated Tuesday, September 18th. The stock was sold at an average price of $40.00, for a total value of $518,080.00. Following the transaction, the chief executive officer now directly owns 12,952 shares of the company’s stock, valued at approximately $518,080. The disclosure for this sale can be found here. Insiders have sold 101,039 shares of company stock valued at $3,465,020 in the last three months. 6.60% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Partner Investment Management L.P. purchased a new position in shares of Audentes Therapeutics during the second quarter worth about $162,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Audentes Therapeutics during the second quarter worth about $226,000. Quantitative Systematic Strategies LLC purchased a new position in shares of Audentes Therapeutics during the second quarter worth about $231,000. Los Angeles Capital Management & Equity Research Inc. purchased a new position in shares of Audentes Therapeutics during the second quarter worth about $232,000. Finally, State Board of Administration of Florida Retirement System purchased a new position in shares of Audentes Therapeutics during the second quarter worth about $332,000. 84.48% of the stock is owned by institutional investors.
Shares of BOLD traded down $0.38 during midday trading on Friday, hitting $24.07. 500 shares of the company traded hands, compared to its average volume of 638,123. Audentes Therapeutics has a one year low of $19.62 and a one year high of $46.18. The stock has a market cap of $1.04 billion, a PE ratio of -7.18 and a beta of 1.91.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
Featured Article: How does inflation affect different investments?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.